

iKnowMedSM Generation 2

MIPS 462 Bone Density Test for Prostate Cancer Patients

In this lesson, you will learn the required steps for **MIPS# 462 Bone Density Evaluation** prior to **Androgen Deprivation Therapy (ADT)** for patients with prostate cancer.

Required:

- EM visit during the reporting year
- Diagnosis of Prostate Cancer on problem list
- Documentation of bone density test performed **prior to treatment ordered or no longer than 3 months after treatment ordered**
- Androgen Deprivation therapy ordered or given
 - ADT = orchiectomy (surgical castration), Leuprolide, Goserelin, Triptorelin, Leuprolide mesylate, Degarelix, Relugolix

Exclusion:

- Patient refused bone density evaluation

ADD PROBLEM

1. Under the Problems tab, click **ADD PROBLEM**.
2. After selecting prostate cancer and adding date of diagnosis, click **NEXT**.

3. To document the bone density test, scroll down to **Bone Density** in the details column.
4. If the test has been performed, check next to **Performed**.
5. Click **SAVE & CLOSE**.

iKnowMedSM Generation 2

Bone Density [clear](#)

☐ Performed

☐ Not performed

☒ Patient refused

6. If the patient refused the test, check next to **Patient refused**.

New Orders (0) Medications (0) Regimens (0)

Regimen Search

Diagnosis/Problem

Primary malignant neoplasm

SEARCH FOR REGIMENS

Additional Data

Clear Value Plus - Pathway Decision Support

Quincy Hart (69 / M) - Hospice

MRN: 98765
DOB: 12/07/1953
Insurance:

Clear Value PlusSM

Known risk group determination required

The guideline requires a risk group determination to determine a guideline recommendation.

Medical Info **Value Pathways Evidence** Filter Chemotherapies by

Lauren's Abraxane Q21D

Leuprolide (2-3 Yrs) (ADT) (Secondary Hormone Tx)

Leuprolide (2-3 Yrs) + Abiraterone + Docetaxel + Prednisone (ADT + Chemo) (Secondary Hormone Tx)

Leuprolide (2-3 Yrs) + Abiraterone + Prednisone (ADT + Chemo) (Secondary Hormone Tx)

Leuprolide (2-3 Yrs) + Apalutamide (ADT + Chemo) (Secondary Hormone Tx)

Leuprolide (2-3 Yrs) + Darolutamide + Docetaxel (ADT + Chemo) (Secondary Hormone Tx)

Leuprolide (2-3 Yrs) + Enzalutamide (ADT + Chemo) (Secondary Hormone Tx)

SAVE CANCEL

7. Using Clear Value Plus, order the appropriate androgen deprivation therapy.

iKnowMedSM Generation 2

The screenshot shows the 'Flowsheet' tab in the iKnowMed interface. At the top, there are navigation tabs: 'Chart Summary', 'Clinical Profile', 'Flowsheet' (selected), and 'Orders'. Below the tabs, there's a 'Find:' search bar. A date selector shows '10/18/23 (Wed)'. A list of medical orders is displayed, with a red box highlighting the 'HORMONE THERAPY' section. This section includes 'Darolutamide Oral' (300 mg bid) and 'Goserelin Subcutaneous' (3.6 mg). A yellow circle with the number 8 points to the 'R' icon next to the Darolutamide entry.

8. Use the Flowsheet tab to view the ordered therapy.

This is a close-up of the therapy entry from the previous screenshot. It shows the date '10/18/23 (Wed)' and the patient name 'San Francisco Medica...'. The therapy entry is 'C1D1 (Zzalexander, S...'. A red box highlights the 'R' icon next to '300 mg bid' and the 'G' icon next to '3.6 mg'. A yellow circle with the number 9 points to the 'R' icon.

9. If the ADT **was ordered or given**, this will meet the denominator inclusion requirements.

This concludes the lesson for the required documentation for **MIPS# 462 Bone Density Evaluation prior to Androgen Deprivation Therapy (ADT) for patients with prostate cancer.**